Expression and significance of DOK2 in colorectal cancer

Wen,Xianmei; Zhou,Muxiu; Guo,Yong; Zhu,Yanwu; Li,Hong; Zhang,Lu; Yu,Long; Wang,Xiaocheng; Peng,Xiaochun

doi:10.3892/ol.2014.2672

Expression and significance of DOK2 in colorectal cancer

Authors:
- Xianmei Wen
- Muxiu Zhou
- Yong Guo
- Yanwu Zhu
- Hong Li
- Lu Zhang
- Long Yu
- Xiaocheng Wang
- Xiaochun Peng
View Affiliations

Affiliations: Department of Pathology, 161st Central Hospital of the People's Liberation Army, Wuhan, Hubei, P.R. China, Department of Pathophysiology, Medical School of Yangtze University, Jingzhou, Hubei, P.R. China
Published online on: November 5, 2014 https://doi.org/10.3892/ol.2014.2672
Pages: 241-244

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A reduction in the levels of docking protein 2 (DOK2) expression has previously been reported in lung adenocarcinoma and gastric cancer, indicating that this protein acts as a tumor suppressor in solid tumors. The aim of the current study was to determine the significance of DOK2 in colorectal cancer. The study consisted of 102 patients who underwent curative surgery for colorectal cancer. Histopathological and immunohistochemical analysis of DOK2 protein expression levels was performed in issue samples, and univariate and multivariate analyses were used to investigate the correlation between prognosis and the clinicopathological parameters. DOK2 expression was confirmed in the normal colorectal mucosa tissues, which is consistent with the literature, whereas 34 out of 102 (33.3%) tumor specimens were negative. The results revealed that recurrence was more likely to develop in DOK2(‑) patients compared with DOK2(+) patients. The DOK2(‑) patients also exhibited a poorer five‑year overall survival rate (59.1%) compared with the DOK2(+) group (76.4%; P=0.0328). These results indicate that DOK2 may potentially be used as a marker of poor prognosis in patients with colorectal cancer following curative resection.

View Figures

View References

1	Kim MJ, Kang YU, Kim CS, Choi JS, Bae EH, et al: Proteinuria as a risk factor for mortality in patients with colorectal cancer. Yonsei Med J. 54:1194–1201. 2013. View Article : Google Scholar : PubMed/NCBI
2	Lin L, Piao J, Gao W, Piao Y, Jin G, et al: DEK over expression as an independent biomarker for poor prognosis in colorectal cancer. BMC Cancer. 13:3662013. View Article : Google Scholar : PubMed/NCBI
3	Kreso A, O’Brien CA, van Galen P, Gan OI, Notta F, et al: Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science. 339:543–548. 2013. View Article : Google Scholar
4	Pitule P, Vycital O, Bruha J, Novak P, Hosek P, et al: Differential expression and prognostic role of selected genes in colorectal cancer patients. Anticancer Res. 33:4855–4865. 2013.PubMed/NCBI
5	Zubeda S, Kaipa PR, Shaik NA, Mohiuddin MK, Vaidya S, et al: Her-2/neu status: a neglected marker of prognostication and management of breast cancer patients in India. Asian Pac J Cancer Prev. 14:2231–2235. 2013. View Article : Google Scholar : PubMed/NCBI
6	Jelovac D and Emens LA: HER2-directed therapy for metastatic breast cancer. Oncology (Williston Park). 27:166–175. 2013.
7	Shapochka DO, Zaletok SP and Gnidyuk MI: Relationship between NF-κB, ER, PR, Her2/neu, Ki67, p53 expression in human breast cancer. Exp Oncol. 34:358–363. 2012.
8	Mashima R, Arimura S, Kajikawa S, Oda H, Nakae S, et al: Dok adaptors play anti-inflammatory roles in pulmonary homeostasis. Genes Cells. 14:56–65. 2013. View Article : Google Scholar
9	Miyagaki H, Yamasaki M, Takahashi T, Kurokawa Y, Miyata H, et al: DOK2 as a marker of poor prognosis of patients with gastric adenocarcinoma after curative resection. Ann Surg Oncol. 19:1560–1567. 2012. View Article : Google Scholar
10	Chen YC1, Hsiao CC, Chen KD, Hung YC, Wu CY, et al: Peripheral immune cell gene expression changes in advanced non-small cell lung cancer patients treated with first line combination chemotherapy. PLoS One. 8:e570532013. View Article : Google Scholar : PubMed/NCBI
11	Qian X, Dong H, Hu X, Tian H, Guo L, et al: Analysis of the interferences in quantitation of a site-specifically PEGylated exendin-4 analog by the Bradford method. Anal Biochem. 465C:50–52. 2014. View Article : Google Scholar : PubMed/NCBI
12	Pericleous M, Mandair D and Caplin ME: Diet and supplements and their impact on colorectal cancer. J Gastrointest Oncol. 4:409–423. 2013.PubMed/NCBI
13	Mohan HM, Evans MD, Larkin JO, Beynon J and Winter DC: Multivisceral resection in colorectal cancer: a systematic review. Ann Surg Oncol. 20:2929–2936. 2013. View Article : Google Scholar : PubMed/NCBI
14	Martin ST, Heneghan HM and Winter DC: Systematic review of outcomes after intersphincteric resection for low rectal cancer. Br J Surg. 99:603–612. 2012. View Article : Google Scholar : PubMed/NCBI
15	Zanutto S, Pizzamiglio S, Ghilotti M, Bertan C, Ravagnani F, et al: Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer. Br J Cancer. 110:1001–1007. 2014. View Article : Google Scholar : PubMed/NCBI
16	Berger AH, Chen M, Morotti A, et al: DOK2 inhibits EGFR-mutated lung adenocarcinoma. PLoS One. 8:e795262013. View Article : Google Scholar : PubMed/NCBI
17	Kim MS, Chung NG, Yoo NJ and Lee SH: Mutational analysis of DOK2 tumor suppressor gene in acute leukemias. Leuk Res. 35:e87–e88. 2011. View Article : Google Scholar : PubMed/NCBI
18	Wiratkapun S, Kraemer M, Seow-Choen F, Ho YH and Eu KW: High preoperative serum carcinoembryonic antigen predicts metastatic recurrence in potentially curative colonic cancer: results of a five-year study. Dis Colon Rectum. 44:231–235. 2001. View Article : Google Scholar : PubMed/NCBI
19	Ren J, Li G, Ge J, Li X and Zhao Y: Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis. Dis Colon Rectum. 55:913–923. 2012. View Article : Google Scholar : PubMed/NCBI
20	Tímár J, Hegedüs B and Rásó E: KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence. Curr Cancer Drug Targets. 10:813–823. 2010. View Article : Google Scholar : PubMed/NCBI